Assembly Biosciences, Inc (ASMB) Stock Price

ASMBStock

$34.07+33.61%52W

Market Cap$693.69M

P/E—

PEG Ratio—

Div yield—

Beta1.13

ASMB Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)3.02%

Price vs S&P 500 (4W)32.80%

VGM Score51.05

Book Value / Share (Quarterly)$12.50

P/TBV (Annual)0.66x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)65.83%

Cash Flow / Share (Quarterly)$-2.51

Price vs S&P 500 (YTD)-12.64%

Net Profit Margin (TTM)-8.98%

EPS (TTM)$-1.29

10-Day Avg Trading Volume0.33M

EPS Excl Extra (TTM)$-1.29

Revenue Growth (5Y)-1.78%

EPS (Annual)$-0.55

ROI (Annual)-2.96%

Net Profit Margin (5Y Avg)-631.81%

Cash / Share (Quarterly)$14.26

Revenue Growth QoQ (YoY)-12.80%

ROA (Last FY)-2.38%

Revenue Growth TTM (YoY)121.11%

EBITD / Share (TTM)$-0.99

ROE (5Y Avg)-92.37%

Operating Margin (TTM)-19.05%

Cash Flow / Share (Annual)$-2.60

P/B Ratio2.93x

P/B Ratio (Quarterly)2.22x

Net Income / Employee (Annual)$-83,900

EV / Revenue (TTM)7.75x

Net Interest Coverage (TTM)-99.13x

ROA (TTM)-3.14%

EPS Incl Extra (Annual)$-0.55

Current Ratio (Annual)5.22x

Quick Ratio (Quarterly)6.49x

3-Month Avg Trading Volume0.21M

52-Week Price Return33.61%

Revenue / Employee (TTM)$973,900

Tangible BV / Share (Quarterly)$42.13

P/S Ratio (Annual)8.05x

Asset Turnover (Annual)0.28x

52-Week High$39.70

Operating Margin (5Y Avg)-656.41%

EPS Excl Extra (Annual)$-0.55

CapEx CAGR (5Y)-50.50%

Tangible BV CAGR (5Y)27.13%

26-Week Price Return14.95%

Quick Ratio (Annual)5.11x

13-Week Price Return22.86%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)6.65x

Enterprise Value$550.91M

Revenue / Share Growth (5Y)-24.79%

Asset Turnover (TTM)0.35x

Book Value / Share Growth (5Y)-31.24%

Revenue / Employee (Annual)$990,500

Pretax Margin (Annual)-8.47%

Cash / Share (Annual)$15.65

3-Month Return Std Dev61.74%

Net Income / Employee (TTM)$-87,400

ROE (Last FY)-2.96%

Net Interest Coverage (Annual)-98.91x

EPS Basic Excl Extra (Annual)$-0.55

P/FCF (TTM)40.95x

Receivables Turnover (TTM)148.47x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.29

Receivables Turnover (Annual)148.47x

ROI (TTM)-4.21%

P/S Ratio (TTM)8.19x

Pretax Margin (5Y Avg)-639.58%

Revenue / Share (Annual)$6.45

Tangible BV / Share (Annual)$42.13

Price vs S&P 500 (52W)15.05%

Year-to-Date Return0.18%

5-Day Price Return-3.43%

EPS Normalized (Annual)$-0.55

ROA (5Y Avg)-48.05%

Net Profit Margin (Annual)-8.47%

Month-to-Date Return35.68%

Cash Flow / Share (TTM)$-1.41

EBITD / Share (Annual)$-1.07

Operating Margin (Annual)-16.76%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-92.37%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.29

P/TBV (Quarterly)0.66x

P/B Ratio (Annual)2.60x

Pretax Margin (TTM)-8.98%

Book Value / Share (Annual)$13.04

Price vs S&P 500 (13W)20.91%

Beta1.13x

P/FCF (Annual)25.88x

Revenue / Share (TTM)$4.21

ROE (TTM)-4.21%

52-Week Low$20.23

vGradeC

gGradeC

mGradeB

vgmGradeC

ASMB Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 13, 2026	-$0.53	-$0.20	+61.90%(+$0.33)
Q1 2026	May 7, 2026	-$0.64	-$0.54	+15.18%(+$0.10)
Q4 2025	Mar 19, 2026	-$0.85	$2.48	+392.91%(+$3.33)
Q3 2025	Nov 10, 2025	-$0.65	-$0.72	-10.20%(-$0.07)
Q2 2025	Aug 6, 2025	-$1.73	-$1.33	+23.12%(+$0.40)

ASMB Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.30

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
ASMBAssembly Biosciences, Inc	C	C	B	$34.07
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Assembly Biosciences, Inc

Assembly Biosciences is a clinical-stage biotechnology company developing two oral therapeutic platforms: one targeting hepatitis B virus (HBV) infection, and another addressing microbiome dysbiosis. Its lead HBV program employs proprietary core protein Allosteric Modulators—small molecules that inhibit multiple steps of the viral lifecycle to improve cure rates beyond current clinical standards. The HBV program constitutes the majority of the company's revenue.